Danaher Corp. shares rise 1.90% to $180.62, outperforming competitors

6 articles · Updated · MarketWatch · Apr 27

The gain ended a four-day losing streak for Danaher, with trading volume reaching 5.3 million, above its 50-day average of 4.3 million.
Danaher outperformed rivals as Thermo Fisher Scientific and Medtronic saw declines, while Abbott Laboratories posted a smaller gain.
Despite Monday's advance, Danaher shares remain 25.61% below their 52-week high of $242.80 set on January 22nd, reflecting ongoing market volatility.

Can one strong quarter in bioprocessing signal a true rebound for Danaher's most vital segment?

Will raised 2026 guidance be enough to push Danaher's stock back toward its 52-week high?

With conflicting analyst views, is Danaher stock an undervalued opportunity or a classic value trap?

Is Danaher's $9.9B Masimo bet a brilliant pivot or a costly distraction from its core business?

Can the famed Danaher Business System unlock the promised $175M in synergies from the Masimo deal?

How will integrating Masimo's AI change Danaher's role in the future of patient care?